targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02740712 | Completed | 1 | 2016-04-01 | null | null | null | null | null | 627,065,227,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03842228 | Recruiting | 1 | 2019-08-12 | null | null | null | null | null | 730,144,441,331 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01199224 | Completed | 1 | 2010-06-01 | null | null | null | null | null | 867,583,395,075 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04276376 | Recruiting | 2 | 2019-04-12 | null | null | null | null | Phase II+ | 987,842,479,924 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02093351 | Completed | 1 | 2014-09-01 | null | null | null | null | null | 996,432,412,882 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02711137 | Terminated | 1 | 2016-05-18 | Terminated | stopped | null | null | null | 996,432,413,204 | Study terminated due to safety issues. | Phase 1/Phase 2 | 18/05/2016 | Terminated | 17/02/2020 | 13/02/2019 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02588105 | Active, not recruiting | 1 | 2015-11-10 | null | null | null | null | null | 1,039,382,085,901 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02210663 | Completed | 1 | 2014-07-01 | null | null | null | null | null | 1,039,382,086,390 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02029001 | Recruiting | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 1,056,561,954,890 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03954366 | Completed | 1 | 2019-05-08 | null | null | null | null | null | 1,065,151,890,498 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |